SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Targeted clinical studies are critically required to assess the effectiveness and safety of pharmacological interventions, notably GLP-1 receptor agonists and SGLT2 inhibitors, primarily in lean NAFLD/NASH populations.